We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioTelemetry is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for BEAT's full-year earnings has moved 19.74% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, BEAT has returned 118.36% so far this year. In comparison, Medical companies have returned an average of 1.12%. As we can see, BioTelemetry is performing better than its sector in the calendar year.
Breaking things down more, BEAT is a member of the Medical Services industry, which includes 34 individual companies and currently sits at #81 in the Zacks Industry Rank. On average, this group has gained an average of 24.61% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.
BEAT will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioTelemetry is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for BEAT's full-year earnings has moved 19.74% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, BEAT has returned 118.36% so far this year. In comparison, Medical companies have returned an average of 1.12%. As we can see, BioTelemetry is performing better than its sector in the calendar year.
Breaking things down more, BEAT is a member of the Medical Services industry, which includes 34 individual companies and currently sits at #81 in the Zacks Industry Rank. On average, this group has gained an average of 24.61% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.
BEAT will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.